Comment
doi: 10.1016/S1470-2045(13)70536-9.
Epub 2013 Nov 13.
Treatment of HER2-positive breast cancer: looking backwards briefly
Affiliations
- PMID: 24239207
- DOI: 10.1016/S1470-2045(13)70536-9
Item in Clipboard
Comment
Treatment of HER2-positive breast cancer: looking backwards briefly
Lancet Oncol.
2013 Dec.
No abstract available
Comment on
-
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial.Lancet Oncol. 2013 Dec;14(13):1317-25. doi: 10.1016/S1470-2045(13)70502-3. Epub 2013 Nov 13. Lancet Oncol. 2013. PMID: 24239210 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
